摘要
目的探讨细胞色素P450酶(cytochromeP450enzymes,CYP)1A2、2C19基因多态性与难治性抑郁症的关联。方法应用聚合酶链反应(PCR)扩增技术及限制性片段长度多态性(RFLP)测定79例难治性抑郁症患者及107名正常对照者CYP1A2C163A、CYP2C19G681A基因多态性。结果两组间基因型及等位基因分布差异无显著性(χ2=3.605,P>0.05;χ2=3.154,P>0.05)。难治性抑郁症患者对照组间基因型及等位基因分布差异无显著性(χ2=0.853,P>0.05;χ2=0.568,P>0.05)。79名患者中46名接受氟西汀合并小剂量利培酮(0.5～2.0mg/d)治疗,将其分为治疗有效组和无效组,两组间CYP1A2C163A(χ2=0.785,P>0.05;χ2=7.142,P>0.05)CYP2C19G681A(χ2=3.008,P>0.05;χ2=2.722,P>0.05)基因型及等位基因分布差异均无显著性。根据CYP2C19G681A基因多态性将患者分为无突变组(G/G型)和突变组(G/A型和A/A型),两组患者CYP1A2C163A基因型及等位基因分布差异无显著性(χ2=0.252,P>0.05;χ2=0.682,P>0.05)。结论CYP1A2C163A和CYP2C19G681A基因多态性与难治性抑郁症无显著关联,不是影响利培酮对氟西汀增效作用的主要因素。
Objective: To investigate the association between cytochrome P450 enzymes 1A2 ,2C19 (CYP1A2, CYP2C19) gene polymorphism and treatment-resistant depression. Methods: Polymerase chain reaction and restriction fragment length polymorphism techniques were used to examine the CYP1A2 C163A and CYP2C19 G681A gene polymorphism of 79 treatment-resistant depression patients and 107 healthy controls. Results:There was no significant difference between two groups in CYP1A2 C163A genotypes and alleles. There was no significant difference between two groups in CYP2C19 G681A genotypes and alleles.Within the 79 treatment-resistant depression patients, there were 46 accepted the risperidone augmentation of fluoxetine. According there response to the therapy, divided the patient into response and non-response two groups. There was no significant difference between two groups in CYP1A2 C163A and CYP2C19 G681A genotypes and alleles. Grouping treatment-resistant depression patients into mutant(G/A and A/A) group and non-mutant group(G/G) by the polymorphism of CYP2C19 gene. There was no significant difference between two groups of the genotype and alleles of CYP1A2 gene. Conclusion:The results suggested there was no association between treatment-resistant depression and the CYP1A2 C163A CYP2C19 G681A gene polymorphism. These two polymorphisms were not the main factors which effects the augmentative effect of the risperidone to fluoxetine.
出处
《上海精神医学》
2005年第2期95-98,共4页
Shanghai Archives of Psychiatry
